Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies

Next Previous
Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Soticlestat (Primary) ; Soticlestat (Primary)
  • Indications Dravet syndrome; Encephalitis; Lennox-Gastaut syndrome; Seizures
  • Focus Therapeutic Use
  • Acronyms ELEKTRA
  • Sponsors Ovid Therapeutics; Takeda

Most Recent Events

  • 05 May 2023 According to an Ovid Therapeutics media release post-hoc analysis data from this study were presented at the 2023 American Academy of Neurology meeting.
  • 27 Apr 2023 Post hoc analysis results presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
  • 16 Jul 2022 Results assessing efficacy and safety of soticlestat (TAK-935) as adjunctive therapy in children with syndrome or Lennox-Gastaut syndrome, published in the Epilepsia.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top